Clinical Impact of Hypophosphatemia

EP: 1.Background and Causes of Iron Deficiency Anemia

EP: 2.Pathophysiology of Iron Deficiency Anemia

EP: 3.Symptoms and Epidemiology of Iron Deficiency Anemia

EP: 4.Diagnosis and Common Comorbidities Seen With Iron Deficiency Anemia

EP: 5.Monitoring Patients With Iron Deficiency Anemia After Diagnosis

EP: 6.Oral vs IV Iron in Clinical Practice

EP: 7.FDA-Approved IV Iron Formulations

EP: 8.Factoring in Safety Considerations With IV Iron Products

EP: 9.Adverse Effects Associated With Hypophosphatemia

Now Viewing

EP: 10.Clinical Impact of Hypophosphatemia

EP: 11.Clinical and Economic Consequences of Nonadherence to IV Iron

EP: 12.Adherence and Time Spent Receiving IV Iron Infusions

EP: 13.Step Edits Associated with IV Iron Therapies

EP: 14.The Future of IV Iron Administration

EP: 15.Closing Thoughts on Iron Deficiency Anemia

Video content above is prompted by the following:

• Considering the incidence of hypophosphatemia in patients with IDA was significantly lower with the use of FDI and FXT than with FCM therapy, how does this impact the choice of treatment?
• How do you monitor phosphate levels?
• A retrospective analysis found a significantly higher combined event rate of fracture, radiological signs of osteomalacia, and kidney stones among patients treated with FCM than after ferric derisomaltose (FDI) treatment. Do these results impact your clinical decision-making?
• What potential interventions or preventative measures could be taken to mitigate the risk of hypophosphatemia in patients receiving IV iron formulations?